Compare Johnson & Johnson (JNJ) vs Morgan Stanley (MS) Price & Performance

Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.

The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.

Morgan Stanley (MS) trades at $210.97, down 2.09% over the past day, with a bullish technical signal from moving averages and a consensus analyst price target of $241.36. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $3.46 surpassing estimates of $2.89. Revenue growth accelerated to $66.0 billion in 2025, up from $57.6 billion in 2024, while net income margin improved to 25.56%. Recent developments include leading Anthropic's upcoming IPO and expanding AI integration in wealth management services.

The outlook remains positive given strong earnings momentum, analyst bullishness, and strategic initiatives in high-growth areas like AI and IPO advisory. Key risks include volatile cash flows from operations, rising debt levels, and sensitivity to financial market conditions. The stock offers potential upside to analyst targets but requires monitoring of operational cash generation and macroeconomic headwinds affecting the financial sector.